943134-39-2

943134-39-2 structure

Name: GAP-134
Chemical Name: (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid
CAS Number: 943134-39-2
Molecular Formula: C₁₄H₁₇N₃O₄
Molecular Weight: 291.30200
Catalog: Signaling Pathways Cytoskeleton Gap Junction Protein
Create Date: 2018-06-12 11:32:07
Modify Date: 2024-01-10 12:10:12
Danegaptide (GAP-134), a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.

Name	(2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid
Synonyms	zp1609 danegaptide gap-134 unii-pa0y7735at

Description	Danegaptide (GAP-134), a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.
Related Catalog	Signaling Pathways >> Cytoskeleton >> Gap Junction Protein Research Areas >> Cardiovascular Disease
Target	Gap junction.
In Vitro	Gap junction uncoupling can alter conduction pathways and promote cardiac re-entry mechanisms that potentiate many supraventricular arrhythmias, such as atrial fibrillation (AF) and atrial flutter (AFL). Gap junction modifier Danegaptide (GAP-134), showed consistent efficacy on measures of conduction and AF/AFL inducibility in the canine sterile pericarditis model. Danegaptide (GAP-134) is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, as already confirmed in phase I clinical trials.
References	[1]. De Vuyst E, Boengler K, Antoons G, et al. Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. Br J Pharmacol. 2011 Jun;163(3):469-83. [2]. Laurent G, Leong-Poi H, Mangat I, et al. Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs. Circ Arrhythm Electrophysiol. 2009 Apr;2(2):171-8. [3]. Hennan JK, Swillo RE, Morgan GA, et al. GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Cardiovasc Pharmacol Ther. 2009 Sep;14(3):207-14. [4]. Rossman EI, Liu K, Morgan GA, et al. The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33. [5]. Eugene L. Piatnitski Cheklera, John A. Buterab, Li Dib, Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents. Bioorganic & Medicinal Chemistry Letters. 2009,19(16): 4551-4554

Molecular Formula	C₁₄H₁₇N₃O₄
Molecular Weight	291.30200
Exact Mass	291.12200
PSA	116.22000
LogP	0.64220
Storage condition	2-8℃

943134-34-7

943134-39-2

Literature: Bioorganic and Medicinal Chemistry Letters, , vol. 19, # 16 p. 4551 - 4554

4530-20-5

65-85-0

176486-63-8

943134-39-2

Literature: US2007/149460 A1, ; Page/Page column 33-34 ; US 20070149460 A1

Precursor 4
943134-34-7 4530-20-5 65-85-0 176486-63-8
DownStream 0

943134-39-2	943133-81-1
198284-64-9	197250-15-0
14914-27-3	849662-80-2
15701-09-4	81065-76-1
64704-31-0	1008448-19-8
1218908-81-6	2034262-78-5
2034286-88-7	90874-83-2
2034484-07-4	2034262-85-4
1785533-56-3	2034471-39-9
2034484-22-3	2034484-15-4